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Design, synthesis and in vitro and in vivo biological evaluation of flurbiprofen
amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory
potential analgesic agents
Alessandro Deplanoa# , Jessica Karlssonb†# , Federica Moracac,d , Mona Svenssonb†, Claudia Cristianoc ,
Carmine Marco Morgilloe , Christopher J. Fowlerb† , Roberto Russoc , Bruno Catalanottic and Valentina
Onnisa
aUnit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, Department of Life and Environmental Sciences, University of Cagliari,
Monserrato, Italy; bDepartment of Integrative Medical Biology, Umeå University, Umeå, Sweden; cDepartment of Pharmacy, University of Naples
Federico II, Naples, Italy; dNet4Science srl, University “Magna Graecia”, Catanzaro, Italy; eDrug Discovery Unit, Wellcome Centre for Anti-
Infectives Research, School of Life Sciences, University of Dundee, Dundee, UK
ABSTRACT
Compounds combining dual inhibitory action against FAAH and cyclooxygenase (COX) may be potentially
useful analgesics. Here, we describe a novel flurbiprofen analogue, N-(3-bromopyridin-2-yl)-2-(2-fluoro-
(1,1’-biphenyl)-4-yl)propanamide (Flu-AM4). The compound is a competitive, reversible inhibitor of FAAH
with a Ki value of 13nM and which inhibits COX activity in a substrate-selective manner. Molecular model-
ling suggested that Flu-AM4 optimally fits a hydrophobic pocket in the ACB region of FAAH, and binds
to COX-2 similarly to flurbiprofen. In vivo studies indicated that at a dose of 10mg/kg, Flu-AM4 was active
in models of prolonged (formalin) and neuropathic (chronic constriction injury) pain and reduced the spi-
nal expression of iNOS, COX-2, and NFjB in the neuropathic model. Thus, the present study identifies Flu-
AM4 as a dual-action FAAH/substrate-selective COX inhibitor with anti-inflammatory and analgesic activity
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The endogenous cannabinoid system is involved in a number of
physiological functions, including the regulation of pain1.
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the two
best-characterised endocannabinoids identified to date. They are
synthesised on demand from membrane lipids, after which they
are released and bind and activate the cannabinoid receptors (CB)
that mediate multiple intracellular signal transduction pathways.
Endocannabinoids are tightly regulated not only with respect to
their biosynthesis but also with respect to their degradation. The
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two major hydrolytic enzymes responsible for the catabolism of
AEA and 2-AG in the brain are fatty acid amide hydrolase (FAAH)2,
and monoacylglycerol lipase (MAGL)3, respectively.
FAAH is a dimeric enzyme with a complex catalytic site charac-
terised by three main interaction sites: the membrane access
channel (MAC) where two charged residues favour the entrance of
the polar head groups of fatty acid substrates, an adjacent “acyl-
chain binding” cavity which likely contributes to the accommoda-
tion of substrates during catalysis, and a solvent-exposed
“cytosolic port” (CP) which represents access to the cytosolic com-
partment of the cell. Once the substrate is bound to FAAH, the
catalytic reaction occurs in the core of its binding site where an
unusual catalytic triad (Ser241 Ser217 Lys142) performs the
hydrolysis of the AEA. This occurs in two steps: firstly, a deproto-
nated Lys142 activates Ser241 through a proton exchange chain
involving Ser217 leading to the protonation of Lys142. Then, the
activated Ser241 attacks the substrate carbonyl group allowing
the protonation of the leaving group ethanolamine which exits
the enzyme through the CP4. Finally, a reverse proton transfer
between Lys142 and Ser217 occurs, followed by a third proton
transfer that re-establishes the original protonation state of the
FAAH catalytic triad and leads to the formation of arachi-
donic acid.
Given the role of FAAH in the AEA hydrolysis, several classes of
FAAH selective inhibitors, have been described in the scientific
and patent literature5. FAAH inhibitors show efficacy in preclinical
models of pain6,7, nausea8, and anxiety9,10 without the occurrence
of tolerance11,12. However, FAAH inhibitors did not exhibit signifi-
cant efficacy in several phase II clinical trials of osteoarthritis13,
painful diabetic neuropathy14, pelvic pain and bladder dysfunc-
tion15 despite being well tolerated with little to no adverse events
reported in each of these studies. One compound that was not
well tolerated in man, however, was the irreversible FAAH inhibi-
tor BIA10-2474, which left one person dead and four others with
severe neurological symptoms16. However, these have been
related to off-target effects due to the compound binds to a num-
ber of other serine hydrolases not exhibited by other FAAH inhibi-
tors evaluated clinically13 and interactions with proteins other
than FAAH are likely to mediate these extreme adverse events17.
These clinical failures highlight the lack of translation between
animal models and humans at least regarding the treatment of
pain associated with inflammation. The real causes of the failure
are not yet been identified, but it is reasonable that in a complex
signalling pathway such as the endocannabinoid system, other
metabolic enzymes and/or endocannabinoid targets may negate
the effects of the FAAH inhibition.
The search for innovative strategies for pain management
remains of key importance. In the literature, there are many exam-
ples of new potential analgesic molecules, which can selectively
interact with known or new targets. Most of them are COX inhibi-
tors18, TRPV antagonists19, or even FAAH inhibitors. Nevertheless,
the usual approach of “one target-one drug” may not be the most
optimal approach, which opens the way to the concept that mole-
cules interacting with more targets that are possibly relevant for
the same disease may show higher therapeutic effects and a safer
biological profile. Therefore, in the last years, several studies have
explored the dual targeting of FAAH and other related targets
involved on signalling pathways of fatty acids and their deriva-
tives, such as FAAH/MAGL inhibitors20, FAAH/TRPV1-receptor
blockers21,22, FAAH/PGF2a-EA-receptor blockers
23, and FAAH/COX-2
inhibitors24–29. In particular, the two latter strategies are based on
the discovery that AEA and 2-AG are also COX-2 substrates that
are converted to biologically active prostamides (prostaglandin
ethanolamides) and prostaglandin glyceryl esters. Indeed, the
prostamide F2a, produced by the cyclooxygenation of AEA, indu-
ces inflammatory and pro-algesic effects30. Therefore, dual block-
ade of FAAH and COX-2 could reduce prostamide biosynthesis
while at the same time increasing AEA concentrations. In support
of this hypothesis, it was seen in a key study that there was a syn-
ergistic interaction between the FAAH inhibitor URB597 and the
non-steroidal anti-inflammatory drug (NSAID) diclofenac with
respect to analgesia. Moreover, the co-administration also
improved safety, whereby the FAAH inhibition lowered the inci-
dence of ulceration produced by the NSAID31.
The development of dual FAAH/COX inhibitors started in 1997
when one of us found that a series of NSAID compounds inhibited
anandamide deamidation albeit with a modest potency32,33. These
findings, in particular for ibuprofen and flurbiprofen (1), led to the
development of amide derivatives with increased FAAH potency
while retaining COX-inhibitory potency. Among these, compounds
deriving from the condensation of ibuprofen and flurbiprofen
with 2-amino-3-methylpyridine (Ibu-AM5 and Flu-AM1) were
identified as the most promising dual inhibitors. In particular, Ibu-
AM5 was 2-3 orders of magnitude more potent than ibuprofen
against FAAH24,34,35 albeit a weaker COX-1 and COX-2 than ibu-
profen. Flu-AM1 was about 60-fold more potent against FAAH
than flurbiprofen, and was a substrate selective inhibitor against
COX-2 in that it inhibited the cyclooxygenation of 2-AG more
potently than the cyclooxygenation of arachidonic acid (AA) by
either form of COX24,26,34. Using molecular docking, molecular
dynamics and evaluation of free energy using a QM/MM
approach, we found that Ibu-AM5 and Flu-AM1 showed very
similar binding modes in the same site located between acyl bind-
ing channel (ACB) and the MAC35.
Although these FAAH/COX compounds look very promising
in vitro, the only in vivo data so far presented were with Ibu-AM5,
which showed efficacy in a model of visceral pain without produc-
ing ulcerations21,22. An alternative approach, to combine the ele-
ments of flurbiprofen and the irreversible FAAH inhibitor URB597,
led to a FAAH/COX dual inhibitor that was active in models of
inflammation and also did not produce ulcerations36, suggesting
that this profile is a class effect of FAAH/COX dual inhibitors.
Finally, a hydrogen sulphide releasing analogue of ketoprofen
with enhanced FAAH inhibitory properties compared to ketopro-
fen has recently been shown to produce analgesic effects without
gastrointestinal damage37.
With respect to improving the potency of our compounds, we
found that for Ibu-AM5, the replacement of the 2-amino-3-meth-
ylpyridine moiety with a 2-amino-3-halolpyridine caused an
increased potency towards FAAH and a selective inhibition of
COX-2 when 2-AG is used as substrate38,39. In particular the N-(3-
bromopyridin-2-yl)-2-(4-isobutylphenyl)propanamide (Ibu-AM68)
and 2-(6-chloro-9H-carbazol-2-yl)-N-(3-chloropyridin-2-yl)propana-
mide (Carpro-AM6) showed the best dual FAAH/COX-2 inhibition
activity. In the present paper we report the design, synthesis, and
the in vitro and in vivo evaluation of the pharmacological activity
of a new series of halogenated flurbiprofen amide derivatives,
retaining the COX inhibition profile of the leads, but with an
improved FAAH inhibition profile.
Materials and methods
General methods
Anandamide [ethanolamine-1-3H] (specific activity 2.22 TBq mmol-
1) was purchased from American Radiolabeled Chemicals, Inc
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(St.Louis, MO). Ovine COX-1 (cat. no. 60100), human recombinant
COX-2 (cat. no. 60122), COX-2 polyclonal antibody (rabbit anti-
mouse, cat #: 160106), arachidonic acid, 2-AG, AEA and URB597
(cyclohexylcarbamic acid 30-carbamoylbiphenyl-3-yl ester) were
purchased from the Cayman Chemical Co. (Ann Arbour, MI, USA).
Substrates were dissolved in ethanol or DMSO as appropriate.
Polyclonal goat anti-rabbit immunoglobulin/HRP was obtained
from Dako (Glostrup, Denmark). Protease inhibitor cocktail set III
was obtained from Merck Millipore (Darmstadt, Germany). All com-
mercially available solvents and reagents were used without fur-
ther purification and were purchased from Sigma-Aldrich (Milan,
Italy). 1H-NMR spectra were recorded on an Inova 500 spectrom-
eter (Varian, Palo Alto, CA), 13C-NMR spectra were recorded on a
Bruker Advance III HD 600. The chemical shifts (d) are reported in
part per million downfield from tetramethylsilane (TMS), which
was used as internal standard, and the spectra were recorded in
hexadeuteriodimethylsulphoxide (DMSO-d6). Infra-red spectra were
recorded on a Vector 22 spectrometer (Bruker, Bremen, Germany).
The main bands are given in cm1. Positive-ion electrospray ion-
isation (ESI) mass spectra were recorded on a double-focusing
MAT 95 instrument (Finnigan, Waltham, MA) with BE geometry.
Melting points (mp) were determined on a SMP1 Melting Point
apparatus (Stuart Scientific, Stone, UK) and are uncorrected. All
products reported showed spectra in agreement with the assigned
structures. The purity of the tested compounds was determined
by combustion elemental analyses conducted by the
Microanalytical Laboratory, Department of Chemical and
Pharmaceutical Sciences of the University of Ferrara with a MT-5
CHN recorder elemental analyser (Yanagimoto, Kyoto, Japan) and
the values found were within 0.4% of theoretical values.
General procedure for synthesis of flurbiprofen amides
The solution of Flurbiprofen (1) (0.24 g, 1mmol), EDC (0.19 g,
1.1mmol) and HOBt (0.13 g, 1mmol) in anhydrous MeCN (10ml)
was stirred at r.t., after 30min the opportune amine (1mmol). The
mixture was stirred at r.t. for 72 h and the solvent was then
removed under vacuum. The residue was dissolved in AcOEt
(20ml) and washed sequentially with brine (2 5ml), 10% citric
acid (2 5ml), saturated NaHCO3 aqueous solution (2 5ml) and
water (2 5ml). The organic layer was dried over anhydrous
Na2SO4 and evaporated under vacuum to give the title amides.
2–(2-Fluoro-(1,1’-biphenyl)-4-yl)-N-(3-(trifluoromethyl)pyridin-2-
yl)propanamide (Flu-AM3)
Obtained following the general procedure by the condensation
between flurbiprofen and 2-amino-3-(trifluoromethyl)pyridine.
Yield 45%. m.p. 110–112 C. 1H NMR (DMSO-d6) d 1.45 (d,
J¼ 7.0 Hz, 3H, CH3), 3.99 (m, 1H, CH), 7.28–8.73 (m, 11H, Ar), 10.39
(s, 1H, NH). IR (Nujol) 3267, 1673, 1583, 1515 cm1. m/z 389
(MþH)þ. Elemental analysis: calculated for C21H16F4N2O (388.37)%
C 64.95; H 4.15; N 7.21; found % C 65.00; H 4.14; N 7.17.
N-(3-Bromopyridin-2-yl)-2-(2-fluoro-(1,1’-biphenyl)-4-yl)propana-
mide (Flu-AM4)
Obtained following the general procedure by the condensation
between flurbiprofen and 2-amino-3-bromopyridine. Yield 60%.
m.p. 89–90 C. 1H NMR (DMSO-d6) d 1.45 (d, J¼ 7.0 Hz, 3H, CH3),
3.99 (q, J¼ 7.0 Hz, 1H, CH), 7.23-8.42 (m, 11H, Ar), 10.35 (s, 1H,
NH). 13C NMR (DMSO-d6) d 18.4, 44.7, 115.2, 115.3, 115.4, 117.6,
124.2 (2 C), 128.0 (2 C), 128.8, 128.9 (2 C), 142.2, 143.2, 143.3, 147.7,
158.3, 159.9, 175.2. IR (Nujol) 3265, 1667, 1511 cm1. m/z 399,
401(MþH)þ. Elemental analysis: calculated for C20H16BrFN2O
(398.26)% C 60.17; H 4.04; N 7.02; found % C 60.25; H 4.06; N 6.99.
N-(3-Chloropyridin-2-yl)-2-(2-fluoro-(1,1’-biphenyl)-4-yl)propana-
mide (Flu-AM6)
Obtained following the general procedure by the condensation
between flurbiprofen and 2-amino-3-chloropyridine. Yield 60%.
m.p. 61–63 C. 1H NMR (DMSO-d6) d 1.48 (d, J¼ 7.0 Hz, 3H, CH3),
4.01 (q, J¼ 7.0 Hz, 1H, CH), 7.30–7.56 (m, 9H, Ar), 7.98 (d,
J¼ 8.0 Hz, 1H, Ar), 8.40 (m, 1H, Ar), 10.41 (s, 1H, NH). 13C NMR
(DMSO-d6) d 18.4, 44.6, 115.1, 115.3, 123.3, 124.2 (2 C), 127.9 (2 C),
128.7, 128.8 (2 C), 130.6, 130.7, 138.9, 147.0, 148.0, 158.1, 159.8,
171.9. IR (Nujol) 3280, 1671, 1578 cm1. m/z 327, 329 (MþH)þ.
Elemental analysis: calculated for C20H16ClFN2O (326.75)% C 67.70;
H 4.55; N 7.90; found % C 67.63; H 4.54; N 7.93.
Computational methods
QM optimisation and electrostatic potential
Quantum mechanics (QM) calculations have been used to evaluate
the strength of interaction between the ligands (FluAM-1 and
FluAM-4) and the rat FAAH (rFAAH) Phe381 sidechain, and to ana-
lyse the electrostatic potential surface (ESP) of the compounds.
The starting conformation was retrieved from the published
FluAM-1 binding mode35. The Phe381 and fluoro-biphenyl moi-
eties of the ligand were fixed during QM optimisation to adjust
the geometry of the complex ligand:Phe381 using Gaussian soft-
ware40 at B3LYP/6–311þG(d,p) level of theory. Interaction energy
(DE) between a ligand (L) and the Phe381 (P) was calculated as:
DE ¼ ELP–ðEL þ EPÞ
where ELP, EL and EP are the energies of the ligand:Phe381 com-
plex, the ligand alone and the Phe381 alone, respectively.
Electrostatic potential maps were generated on the optimised
conformations of the compounds. ESP surfaces were represented
in pymol 2.3.241 using 0.004 isodensity surface and consequently
the surfaces were mapped by colour where the ESP varies from
red (the most negative) to blue (the most positive).
FAAH/COXs receptors and ligands preparation
The crystal structure of rFAAH was downloaded from the Protein
Data Bank (PDB ID: 3QK542). For the COXs isoforms, the ovine
COX-1 PDB model 3N8Z43 and the mouse COX-2 PDB model
3RR344 were selected. The presence of the non-selective NSAID
Flurbiprofen as co-crystallized ligand was used as main selection
criterion of the two isoforms. However, the human COX-2 com-
plexed with flurbiprofen was not found, thus the mouse COX-2
was chosen as isoform-2 target, given its 87% identity with human
COX-2. Both monomers A and B of rFAAH and COXs were treated
with the Protein Preparation Wizard tool implemented in Maestro
ver. 11.1245, in order to add all the hydrogen atoms and assign
the correct bond orders. Subsequently, the co-crystallized ligands
(QK5 and Flurbiprofen) and water molecules were removed.
Residue Lys142 of rFAAH was considered in its deprotonated
form, according to the proposed catalytic mechanism46. The 3D
structure of Flu-AM3-6 amides described above were built using
the Graphical User Graphical User Interface (GUI) of Maestro ver.
11.12. Their protonation state at pH 7.4 in water has been calcu-
lated using the Epik module. Finally, each compound was then
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subjected to a minimisation protocol as described in our previ-
ous work38.
Molecular docking
To investigate in detail the recognition of the Flurbiprofen amide
halogenated derivatives Flu-AM3-6 to rFAAH and both COXs iso-
forms, docking simulations were carried out with the Glide soft-
ware package, using the Standard Precision (SP) algorithm of the
GlideScore function and the OPLS 2005 force field47. The docking
binding site has been defined by means of a grid box of
29 29 29Å centred in the ligand-binding cavity of rFAAH, and
of 15 15 15Å centred to cover the cyclooxygenase site of both
COX-1 and COX-2. In addition, given the presence of halogen
atoms in the designed ligands that could act both as halogen
bond donors (between the r-hole and a Lewis-base acceptor in
the receptor) and hydrogen bond acceptors (between the lone
pairs and an H-atom donor in the receptor), three different Glide
protocols were adopted in the grid generation: i) default Glide
parameters; ii) halogens treated as halogen bond donors; ii) halo-
gens treated as hydrogen bond acceptors. A total amount of 200
ligand poses was generated and the conformational sampling of
the ligand was enhanced by two times, as reported by the default
setting of Glide. Docking conformations of Flu-AM3-6 were then
clusterized based on their RMSD cut-off of 2 Å.
Molecular dynamics (MD)
The poses 1 and 2 of the most interesting compound Flu-AM4
retrieved by the docking procedure were submitted to 500 ns of
MD simulation. The same docking pose of Flu-AM4 obtained in
monomer A was loaded also in monomer B, then each monomer
has been treated separately for the MD analysis. MD was per-
formed with the AMBER16 software48. Each complex was
immersed in a pre-equilibrated octahedral box of TIP3P water
molecules, and then the system was neutralised. The final systems
contained about 106,000 atoms. All simulations were performed
with the Amber ff14SB force field49 for the protein, while ligand
charges were obtained by computing the ESP by means of the
Gaussian09 package40 using a B3LYP/6–31G DFT level of theory,
and then the restrained electrostatic potential (RESP) charges50
were obtained by a two-stage fitting procedure using
Antechamber51 and the General Amber Force Field (GAFF) force
field52. The geometry of the two systems was minimised using
convergence criterion for the energy gradient set to 0.01 kcal
(mol.Å)1 in three steps, which include: (i) minimisation of hydro-
gen atoms in the system (5000 steps of steepest descent and
10000 steps of conjugate gradient); (ii) minimisation of hydrogen
atoms, water molecules and counterions (2000 steps of steepest
descent and 18,000 steps of conjugate gradient); finally (iii) the
whole system (2000 steps of steepest descent and 18,000 steps of
conjugate gradient). Thermal and pressure equilibrations of the
systems were performed in three steps: 200 ps increasing the tem-
perature from 0 to 298 K restraining the protein backbone and lig-
and; then, 800 ps in which the restraining force was gradually
decreased and, finally, 200 ps were performed in order to equili-
brate the system density at constant pressure (1 bar), constant
temperature (298 K). Production runs of 500 ns were then per-
formed under NPT conditions and a time step of 2fs. Trajectories
and data were processed and analysed using the cpptraj module53
and the Visual Molecular Dynamics (VMD) graphics54. Combined
clusterization analysis was carried out with the DBSCAN algo-




Ethical permission for the in vitro animal experiments was
obtained from the Umeå Ethical Committee for Animal Research,
Umeå, Sweden (n A67-09). Brains (minus cerebella) from adult
Wistar or Sprague-Dawley rats (killed by decapitation) or from
male B6CBAF1/J mice (killed by cervical dislocation), stored at
80 C, were thawed, weighed and homogenised in cold 20mM
HEPES, 1mM MgCl2, pH 7.0 and thereafter centrifuged at 35000 x
g for 20min at 4 C. Homogenates were washed (by centrifugation
followed by resuspension in the buffer) twice and incubated at
37 C for 15min in order to hydrolyse all endogenous FAAH sub-
strates. After a further centrifugation, pellets were resuspended in
50mM Tris-HCl buffer, pH 7.4, containing 1mM EDTA and 3mM
MgCl2, and frozen at 80 C in aliquots until used for the assay.
For the FAAH assay56 test compounds, homogenates (usually
0.5–0.8 mg protein per assay, diluted with 10mM Tris-HCl, 1mM
EDTA pH 7.4) and 25mL of [3H]AEA in 10mM Tris- HCl, 1mM
EDTA, pH 7.4, containing 1% w/v fatty acid-free bovine serum
albumin, final substrate concentration of 0.5mM) were incubated
for 10min at 37 C (final assay volume 200 mL). Reactions were
stopped by placing the tubes on ice. Final assay concentrations of
the solvents used for the compounds (ethanol or DMSO) were in
the range 1–5%. Activated charcoal (80 mL þ 320 mL 0.5M HCl)
was added and the samples were mixed and left at room tem-
perature for about 30min. Following centrifugation at 2000 g for
10min, aliquots (200mL) of the supernatants were analysed for
tritium content by liquid scintillation spectroscopy with quench
correction. Blank values were obtained by the use of buffer rather
than homogenate. In general, FAAH assays upon three homoge-
nates were undertaken using separate inhibitor dilution series
(from a stock solution), with 6 concentrations of inhibitor in half-
log concentrations (i.e. 1, 3, 10mM etc) ranging from 0.3–100 mM.
Data were expressed as % of vehicle control and analysed using
the algorithm log(inhibitor) vs. response - variable slope (four
parameters) built into the GraphPad Prism computer program for
the Macintosh (GraphPad Software Inc., San Diego, CA). Two dif-
ferent curve fits were chosen: one where the top (uninhibited)
value was set to 100 and the bottom (maximum inhibition) was
set to 0, and one where the top was set to 100 and the bottom
allowed to float. The best model (when the bottom value returned
>0) was chosen by Akaike’s informative criteria. For the com-
pounds here, the simpler model was always returned. Since the
program uses log10 inhibitor concentrations, the IC50 values for
the inhibitable fraction are derived from the corresponding
-log10(IC50) (pI50) values. Hence the SE values are for the pI50 val-
ues rather than the IC50 values. In consequence, we report both
pI50 and IC50 values to indicate the SE values. With this assay, the
selective FAAH Inhibitor URB597 completely blocked the hydroly-
sis of 0.5 mM [3H]AEA by rat brain homogenates at a concentration
of 100 nM and caused 98% inhibition at 10 nM following a prein-
cubation of 60min between inhibitor and substrate, indicating
that the assay as used here is specific for FAAH57. For the kinetic
experiments, the data were analysed using algorithms for com-
petitive, mixed-type or non-competitive inhibition in the
GraphPad Prism program, and the best fit determined using
Akaike’s Informative Criteria.
COX-1 and 2 inhibition experiments
The assay was performed according to Meade et al.58 with minor
modifications27. An oxygen electrode chamber with integral stir-
ring (Oxygraph System, Hansatech Instruments, King’s Lynn, U.K.)
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was calibrated daily to ambient temperature and air pressure. The
assay buffer contained 100mM Tris-HCl buffer pH 7.4, 1 mM haem-
atin, 2mM phenol, 5mM EDTA, 10mM substrate (arachidonic acid
or 2-AG) (final assay volume was 2ml). After addition of Flu-AM4
dissolved in ethanol (final assay concentration 1%), a baseline was
established for 5min before initiation of reaction by addition of
200 units of either ovine COX-1 or human recombinant COX-2.
The change in oxygen consumption as a measurement of enzyme
activity was monitored for approximately 5min.
In vivo pharmacological activity
Animals
The behavioural experiments were performed on CD1 male mice
(25–30 g Charles Rivers-Italy). They were housed in the animal care
facility of the Department Experimental of Pharmacology,
University of Naples. The animals were acclimated to their envir-
onment for 1week and had ad libitum access to standard rodent
chow pellets VRF1 (purchased from Special Diet Service-SDS). All
behavioural tests were performed between 9:00 AM and 13:00 PM,
and the animals were only used once. Procedures involving ani-
mals and their care were conducted in conformity with inter-
national and national law and policies (EU Directive 2010/63/EU
for animal experiments). The procedures reported here were
approved by the Institutional Committee on the Ethics of Animal
Experiments (CSV) of the University of Naples “Federico II” and by
the “Ministero della Salute”, protocol no. 2014–0084607. At the
end of all experiments for all pain models, the animals were
euthanized by CO2 overdose. As suggested by the animal welfare
protocol, all efforts were made to minimise animal suffering and
to use only the number of animals necessary to produce reliable
scientific data.
Drug treatments
During this study, Flu-AM4 was administered systemically (intra-
peritoneally) and locally (intraplantar 100 microg/paw). For sys-
temic administration, the compound was dissolved in PEG400
20% v/v, TWEEN 80 5% (v/v) and sterile saline and used at differ-
ent doses (1–3–10mg/kg). Vehicle group was only treated with
PEG, TWEEN and sterile saline. For intraplantar administration Flu-
AM4 was dissolved in PEG400 10% v/v, TWEEN 80 5% (v/v) and
formalin 5% in sterile saline.
Formalin-evoked hind-paw licking
Mice received intraplantar injections of formalin in saline (10%,vol/
vol; 10ml/paw). Paw licking was monitored by an observer blind
to the experimental treatment for periods of 0–15min (early
phase) and 15–60min (late phase) immediately after formalin
administration. Flu-AM4 was administrated both by local injection
(100 mg) and systemic administration (10mg/kg).
Carrageenan-induced paw eodema
Paw edoema was induced by a subplantar injection of 0.1ml of
sterile saline containing 1% k-carrageenan (Sigma Aldrich) into the
right hind paw. Paw volumes were measured by a plethysmome-
ter (Ugo Basile, Italy) at different times after the paw injection.
The increase in paw volume was evaluated as the difference
between the paw volume measured (Vm) at each time point (1, 2,
4, 6 and 48 h post carrageenan) and the basal paw volume (Vb)
measured immediately before carrageenan injection (D
volume¼ Vm – Vb).
Mechanical hyperalgesia
Paw withdrawal threshold (PWT) to mechanical pressure was
measured with a Randall-Selitto Analgesy-Meter for mice (Ugo
Basile, Italy). PWT was measured on the ispsilateral paw at 1, 2, 4,
6 and 48 h post carrageenan injection. Each paw was tested twice
per session. Cut-off force was set at 100 g.
Chronic constriction injury (CCI) model of neuropathic pain
Neuropathic pain was induced by ligation of the sciatic nerve as
described previously59. Briefly, mice (n¼ 6 each group) were first
anaesthetised with xylazine (10mg/kg i.p.) and ketamine (100mg/
kg i.p.), and the left thigh was shaved and scrubbed with beta-
dine, then a small incision in the middle left thigh (2 cm in length)
was performed to expose the sciatic nerve. The nerve was loosely
ligated at two distinct sites (spaced at a 2-mm interval) around
the entire diameter of the nerve using silk sutures (7–0). The sur-
gical area was closed and finally scrubbed with betadine. At day 7
and 14 Mechanical Allodynia (von Frey test) and Mechanical
hyperalgesia (Randall-Selitto test) were assessed. In sham-operated
animals, the nerve was exposed but not ligated.
Mechanical allodynia
To assess for changes in sensation or in the development of
mechanical allodynia, sensitivity to tactile stimulation was meas-
ured using the Dynamic Plantar Aesthesiometer (DPA, Ugo Basile,
Italy). Ligated animals were placed in a chamber with a mesh
metal floor covered by a plastic dome that enabled the animal to
walk freely, but not to jump. The mechanical stimulus was then
delivered in the mid-plantar skin of the hind paw. The cut-off was
fixed at 5 g, while the increasing force rate (ramp duration) was
settled at 20 s. The DPA automatically records the force at which
the foot is withdrawn and the withdrawal latency. Each paw was
tested twice per session. This test did not require any special pre-
training, just an acclimation period to the environment and test-
ing procedure. Testing was performed on the ispsilateral (ligated)
paw at day 7 and 14 after ligation, 1 h post dose.
Scheme 1. Synthesis of flurbiprofen amides: (i) EDCI, HOBt, MeCN, r.t. 72 h.
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Statistical analysis
In vivo data are presented as mean± SEM. In CCI experiments,
DPA data are presented as paw withdrawal threshold (g), cold
allodynia data are presented as number of paw withdrawal. The
significance of differences between groups was determined by




On the basis of our previous work on Flu-AM1, we have designed
a novel series of Flu-AM1 derivatives where the pyridine methyl is
substituted by halogen atoms. The most stable binding mode of
Flu-AM1 obtained in the QM/MM calculation showed the methyl
group of the methyl-pyridine moiety located into a hydrophobic
pocket defined by the Met436, Leu404 and Phe381. Taking advan-
tage of these finding, we computationally validated our design
exploring the possibility of enhancing this interaction by substitut-
ing the methyl group with halogens, in order to exploit halogen
bonding of the r-hole of the halogen with the aromatic ring of
Phe381. To evaluate this possibility, we transformed Flu-AM1 into
Flu-AM4 and performed an DFT geometry optimisation with the
program Gaussian at the B3LYP/6–311þG(d,p) level of the con-
formation of the ligand. To this aim, we defined a simplified sys-
tem containing only the ligand and Phe381 and performed a DFT
optimisation to evaluate energetic differences in the CH-p inter-
action when transforming methyl to bromine. The results
(Supporting information Figure S1 and Table S1) clearly showed
the greater tendency of bromine-derivative than methyl derivative
to interact with Phe381.
Synthesis
The target amides of flurbiprofen with halogenated pyridinamines
were synthesised according to the Scheme 1. The amides Flu-AM
3, 4, 6 were obtained by coupling the flurbiprofen (1) with 2-
amino-3-halopyridines in the presence of 1–(3-dimethylamino-
propyl)-3-ethylcarbodiimide hydrochloride (EDCI) and 1-hydroxy-
benzotriazole hydrate (HOBt) in dry acetonitrile (MeCN) solution.
This synthetic pathway was found to be clean and high yielding.
FAAH inhibition
The obtained halogenated amides (Flu-AM3, 4 and 6), along with
the reference compound Flu-AM1 were evaluated for their ability
to inhibit FAAH. The inhibition assays were performed using
0.5 mM [3H]AEA as substrate and rat or mouse brain homogenates
as the enzyme source. The results of these primary assays are
shown in Table 1 and Figure 1(A). The results revealed that the
introduction of a halogenated moiety at 3-position of pyridine
ring resulted in an increased ability to inhibit FAAH as compared
to the reference Flu-AM1. All the new amides showed enhanced
activity as compared with the reference. The replacement of the
methyl on the pyridine ring of Flu-AM1 with a trifluoromethyl
group led to about 4-fold increase in activity (Flu-AM3 IC50
0.11 mM). The introduction in the same position of chlorine or
bromine atom produced further increase in activity being amides
Flu-AM6 and Flu-AM4 with nanomolar potency (IC50 19 and
21 nM respectively, i.e. more than three orders of magnitude
greater than flurbiprofen) and approximately 20-fold more potent
than Flu-AM1.
Mode of inhibition of FAAH by Flu-AM4
The mode of inhibition of FAAH by Flu-AM4 is shown in Figure 1.
The compound acted as a reversible inhibitor of rat brain FAAH
(no time-dependent inhibition, loss of inhibition following dilution
of the enzyme-inhibitor complex prior to addition of substrate).
With respect to kinetics of inhibition, the Flu-AM4 inhibition data
were better fitted by a model assuming competitive inhibition (Ki
value 13 nM) than by a mixed-model inhibition. The compound
was, however, an order of magnitude more potent towards rat
brain FAAH than mouse brain FAAH (pI50 6.37 ± 0.10, IC50 value
430 nM). This is consistent with our previous work with Ibu-AM5
and Flu-AM135 and is presumably related to species differences of
the amino acid compositions in the key binding sites of the
enzymes. Species differences have also been reported for other
types of FAAH inhibitor60,61. Nonetheless, Flu-AM1 has sub-micro-
molar potency in the mouse, which is of relevance for
in vivo studies.
COX inhibitory activity of Flu-AM4
Given the ability of Ibu-AM5 and Flu-AM1 to inhibit COX24,26, we
investigated the ability of Flu-AM4 to inhibit COX-1 and COX-2
(Figure 2). Two substrates were investigated, arachidonic acid (AA,
for both COX isoforms) and 2-AG (for COX-2; COX-1 does not cata-
lyse the cyclooxygenation of this compound). At a concentration
of 10mM, Flu-AM4 completely inhibited the cyclooxygenation of
2-AG by COX-2, while only partially inhibiting the cyclooxygena-
tion of AA by COX-1 (2-AG is not a substrate of COX-1). This pat-
tern of substrate selectivity is similar to that seen with
flurbiprofen and Flu-AM123.
Table 1. pI50 (-logIC50) and the derived IC50 values for inhibition of rat brain
AEA hydrolysis by flurbiprofen amides. In all cases, the maximum inhibition
was 100%.
Compound pI50 IC50 (mM)
Flurbiprofena 4.53 ± 0.02 29
Flu-AM1a 6.36 ± 0.02 0.44
Flu-AM3 6.96 ± 0.12 0.11
Flu-AM4 7.67 ± 0.10 0.021
Flu-AM6 7.72 ± 0.07 0.019
aThe data for flurbiprofen and Flu-AM1, shown for comparative purposes, are
from Ref. 26. Data are means ± s.e.m., n¼ 3–4.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 945
On the basis of enzymatic assays, Flu-AM4 was considered the
most interesting derivative and investigated in vivo.
Molecular modelling: FAAH inhibition
To study the effect of the substitution of the methyl group of Flu-
AM1 with halogens we performed a molecular docking investiga-
tion of the compounds Flu-AM3-6 in monomer A of the crystal
structure of rat FAAH (rFAAH) (PDB ID: 3QK5), with the Standard
Precision (SP) algorithm of the Glide program (Schr€odinger Inc.)
by using three different protocols: i) default parameters ii) halo-
gens treated as electron acceptors (halogen bond) and iii)
halogens treated as hydrogen bond acceptors. The results of all
the protocols, ranked together in both terms of Glide SP score
and cluster population, clearly indicated as favoured poses those
showing the biphenyl moiety pointing towards the catalytic triad
and the pyridine ring entering the MAC (Supporting information
Text S1.1, Table S2 and Figure S2), in a very similar orientation as
found for Flu-AM1 obtained after Molecular Dynamics (MD)
refinement35.
Considering Flu-AM4 as the most promising compound of the
series, we refined the two best docking poses of Flu-AM4 through
500 ns of classical MD simulations. The MD simulations were car-
ried out on the rFAAH homodimer by loading the same docking
pose of Flu-AM4 obtained in both monomers A. MD analysis was
Figure 1. Mode of inhibition of FAAH by Flu-AM4 showing a reversible and competitive mode of FAAH inhibition. Inhibition of rat (unless otherwise shown) brain
[3H]AEA hydrolysis by Flu-AM4. Panel A shows the inhibition curves for both rat and mouse brain homogenates from which the IC50 values were derived. In Panel B,
rat brain homogenates were preincubated for the times shown prior to addition of substrate and incubation for a further 10min. Panel C shows the kinetics of the
inhibition of rat brain [3H]AEA hydrolysis by Flu-AM4. The data were better fitted by a model assuming competitive inhibition (Ki value 0.013mM) than by a mixed
model inhibition. All data are means± s.e.m. (unless hidden by the symbols) n¼ 3–4. In Panel D, rat brain homogenates (at 20-fold normal strength) were preincu-
bated with either vehicle, 0.1, 0.2 or 0.3mM Flu-AM4 for 60min. Aliquots were then diluted 20-fold and assayed for FAAH activity. These are shown as 0.1 ! 0.005,
0.2 ! 0.01 and 0.3 ! 0.015. Concomitantly, Flu-AM4 was added to vehicle-preincubated aliquots to give concentrations of 0.005, 0.01 and 0.015mM (representing
free concentrations after a 20-fold dilution), 0.1, 0.2 and 0.3mM final concentrations. The panel shows the data as % of corresponding control. For a fully reversible
inhibitor, the preincubatedþ diluted samples should match the corresponding “diluted” rather than “concentrated” concentrations added after the preincubation phase
(i.e. the 0.1 ! 0.005 samples should match the 0.005 and not the 0.1mM samples). Data are means± s.e.m. (unless hidden within the symbols), n¼ 3–4.










c0 70% 66% 19% 100% 95%
c1 16% 0% 64% 0% 0%
c2 12% 31% 15% 0% 0%
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performed considering the simulations of the two monomers as
independent of each other, according to previous reports62.
Therefore, four independent MD trajectories were analysed, two
for each pose, for a total MD simulation time of 2 ms. The RMSD
analysis of Flu-AM4 revealed stable trajectories with small fluctu-
ation within 1 Å of the ligand after an initial adjustment within
the hydrophobic ACB channel (Supplementary Figure S3). The
combined clusterization of the four trajectories, performed with
the Density-Based Spatial Clustering of Applications with Noise
(DBSCAN) algorithm55 showed that both docking poses converged
to the same binding mode, represented by a main cluster
accounting for 70% of the overall population (Table 2).
The minimised representative structure of the best MD cluster
(Figure 3(A)) showed an L-shaped conformation of the ligand and
a binding mode mainly based on hydrophobic and aromatic inter-
actions. The terminal phenyl ring fitted a hydrophobic pocket
lined by Ile238, Val276, Ala377, Leu380, and Val495, with the cen-
tral fluorine-substituted phenyl ring resulted stacked between two
T-shaped p-p interactions, with Phe194 and Phe381, and flanked
by Leu192 and Ile491. The bromo-pyridine ring showed hydropho-
bic contacts with Leu404, Leu429, Phe432, Leu433, Met436,
Thr488 and a T-shaped p–p interaction with Trp531. Moreover, the
bromine atom pointed towards Phe381, at a distance of 3.8 Å,
thus indicating the possibility of a direct halogen bond inter-
action. Finally, a discontinuous hydrogen bond interaction (H-
bond) was observed between the carbonyl of the ligand and the
hydroxyl group of Thr488, with an occupancy percentage of 38%
over the MD run. Taken together, the MD results suggested that
the introduction of a bromine instead of the methyl on the pyri-
dine ring induced a slightly different conformational behaviour,
leading to a more compact structure that perfectly fits the hydro-
phobic environment of the ACB. The comparison of the proposed
Flu-AM4 binding mode to that previously published for Flu-AM1
(Supporting information Figure S4) revealed how the different
binding conformations of the two close compounds, likely driven
by different internal interaction of the bromine or the methyl with
the fluorine-substituted phenyl ring, determined a different ability
to exploit the hydrophobic residue that characterises the ACB
Figure 2. Inhibition of COX-1 and COX-2 by Flu-AM4. Inhibition of the activities of ovine COX-1 (towards arachidonic acid, AA) and human recombinant COX-2
(towards either arachidonic acid or 2-AG) by Flu-AM4. Shown are means± s.e.m., n¼ 3 for the change in oxygen tension following addition of enzyme in the presence
of the concentrations of the compounds (mM) shown on the right of each panel. The enzyme isoform and substrate (10lM concentration) used are shown above
each panel. “F” in Panel A refers to 10mM flurbiprofen, used as a positive control for COX-1.
Figure 3. (A) The Flu-AM4 L-shaped conformation (magenta stick) of the best cluster obtained from the DBSCAN analysis and minimised considering the explicit water
molecules. (B) General view of the rFAAH enzyme (PDB ID: 3QK5) complexed with Flu-AM4 in the same conformation (magenta spheres). rFAAH is displayed as wheat
cartoon with the catalytic triad residues Lys142, Ser217 and Ser241 highlighted as magenta sticks. Amino acids involved in ligand/protein interactions with Flu-AM4
are shown as yellow lines. Hydrogen bond interaction between the carbonyl of Flu-AM4 and the hydroxyl group of Thr488 is shown as dashed black line.
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channel. In particular, the biphenyl moiety of Flu-AM4
optimally fit a hydrophobic pocket establishing apolar contacts
with 6 residues, while Flu-AM1 only with 3 residues (Phe194,
Ile238 and Ile491). Therefore, we can conclude that the introduc-
tion of the bromine enhanced the affinity for the FAAH, by means
of the optimisation of hydrophobic interactions within the
ACB channel.
Molecular modelling: COX-2 inhibition
To study the molecular basis of COXs inhibition by Flu-AM4,
docking experiments were carried out on COX-1 and COX-2 iso-
forms (PDB IDs: 3N8Z and 3RR3 respectively). Docking results of
Flu-AM4 in the COX-2 showed a clear preference for a single
pose, strictly resembling the binding mode of the complexed flur-
biprofen (1, Figure 4(B)), with the amide carbonyl oxygen and the
pyridine nitrogen mimicking the interaction of the carboxylic acid
group of 1, directly engaging hydrogen bond interactions with
the key residue Arg120. Accordingly, the analysis of the electro-
static potential surface of compounds Flu-AM1 and Flu-AM4
clearly showed a negative electrostatic potential localised between
the pyridine nitrogen atom and the carbonyl group, supporting
the hypothesis that the capability to retain COX-2 inhibitory prop-
erties is due to the peculiar behaviour of the amide-pyridine
group to mimic the carboxylic group in NSAIDs. Interestingly,
within the COX-1 Flu-AM4 was not able to fit into the known
active site occupied by 1, lacking the key interactions with Arg120
(Figure 4(C)). In accordance with these observations, the resulting
Glide SP scores are consistently higher in the case of COX-1 iso-
form (Supporting Information, Table S3). NSAIDs selectivity
towards COX-2 has been achieved exploiting the different volume
of the orthosteric binding site, mainly due to the presence of
Ile523 in the catalytic domain of COX-1 (Val523 in COX-2), which
reduces the volume of the cyclooxygenase site by closing the
hydrophilic side pocket located above the Arg-120/Tyr-355 resi-
dues63. In our case, docking results of Flu-AM4 against COX-1
highlighted also the role of Leu357 (Phe357 in COX-2) that further
reduces the catalytic pocket, thus hampering the bromine-pyridine
ring to adopt the same binding mode observed in COX-2
(Figure 4(C)).
Flu-AM4 activity in acute and chronic pain mice models
The efficacy of FAAH inhibitors in several animal models of pain
and inflammation have been described6,63,64. Most data are from
irreversible inhibitors, but the reversible FAAH inhibitor OL-135
also reduces mechanical allodynia in a rat spinal nerve ligation
model65. On the basis of enzymatic assays, Flu-AM4 was consid-
ered the most interesting derivative and investigated in vivo in
Figure 4. (A) General view of the COX-1 (dark-green cartoon) and COX-2 isoforms (orange cartoon) complexed, in the cyclooxygenase site, with the best docking
results of Flu-AM4 (dark-green and orange spheres, respectively in COX-1 and COX-2). (B) Best docking pose of Flu-AM4 (orange stick) in the COX-2 isoform, superim-
posed with the co-crystallographic binding mode of flurbiprofen (violet stick) (PDB ID: 3RR3). (C) Best docking pose of Flu-AM4 (dark-green stick) in the COX-1 isoform,
superimposed with the binding mode of Flu-AM4 against COX-2 (orange dots) to highlight the steric hindrance between the bromine atom and the Leu357, which
hampers a full accommodation of Flu-AM4 within the catalytic domain of COX-1. Key enzymes residues Arg120 and Tyr355 in COX-1 and COX-2 are shown as dark-
green and orange lines, respectively. Amino acid residues influencing the binding mode of Flu-AM4 between COX-1 and COX-2 are shown as spheres. Hydrogen bond
interactions are shown as dashed black lines.
Figure 5. Effect of vehicle and Flu-AM4 after A, systemic administration and B,
local application in formalin-induced paw licking. In Panel A, 1 h before formalin
injection, mice were treated with vehicle (white column) and Flu-AM4 (10mg/kg
ip; black columns). In Panel B, mice were treated with vehicleþ formalin in paw
(white column) and Flu-AM4 (100mg) þ formalin in paw (black columns). The
cumulative licking time were counted for 15min (phase I) and 50min (phase II).
Data are shown as mean±SEM of 6 animals per group.  p< 0.01 and 
p< 0.001 vs. vehicle, unpaired t-test.
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order to evaluate its anti-inflammatory and analgesic proprieties.
In particular, we choose acute pain/inflammation animal models,
such as carrageenan and formalin tests, to assess the ability of our
compound to reduce oedema and inflammatory pain. Moreover,
using the CCI model we have determinate the capability of Flu-
AM4 in a chronic neuropathic pain model.
The nocifensive response to formalin injection into the paw is
characterised by two phases, an early sensorial phase (phase I)
lasting the first 15min, and a late inflammatory phase lasting
from 20 to 60min after the injection. This can be evaluated by
determining the amount of time that the animals spend licking or
biting the injected paw (Figure 5 white bars). Systemic Flu-AM4
administration (10mg/kg) was able to reduce the behavioural
responses in both phases (Figure 5(A) black bars, p< 0.001).
Moreover, we also evaluated the activity of Flu-AM4 after local
injection. Co-administration of formalin 5% and Flu-AM4 (100 mg)
reduced the paw licking time in both phases compared to forma-
lin alone, suggesting that peripheral effects of the compound can
contribute to its efficacy in this model (Figure 5(B) black
bars, p< 0.001).
The anti-inflammatory properties of Flu-AM4 were investigated
further in the carrageenan paw oedema model. This is a classic
inflammatory model in which injection of carrageenan induced
plasma extravasation (oedema) and prolonged hyperalgesia until
72 h after injection. Systemic administration of Flu-AM4 (10mg/
kg) reduced paw oedema at 2 and 4 h after carrageenan injection
(Figure 6(A), p< 0.05), moreover, the compound was able to
reduce hyperalgesia seen 2 h after carrageenan (Figure
6(B), p< 0.001).
Finally, we evaluated Flu-AM4 effect at different doses with
respect to the mechanical allodynia and hyperalgesia produced in
a neuropathic pain model, sciatic nerve ligation (CCI). We
observed that 7- and 14-days vehicle CCI-treated mice (ctr)
showed a significant reduction of the paw withdrawal threshold in
both Von Frey and Randall-Selitto tests respect to sham not-
ligated mice (Figure 7; p< 0.001 vs. sham). Systemic Flu-AM4
treatment (1 h before test) significantly decreased the mechanical
allodynia and hyperalgesia. In particular, the high dose, 10mg/kg
increased paw withdrawal latency in both test and in all experi-
mental time (day 7 and 14), the dose of 3mg/kg resulted efficacy
only at 14 days in both tests and on both days 7 and 14. The
dose of 3mg/kg showed efficacy only at the 14-day time point in
both tests, and the 1mg/kg dose did not show any effect.
We evaluated the expression of key factors involved in the
development and maintenance of the inflammatory and pain
state, such as COX-2, iNOS and NFjB in spinal cord of neuro-
pathic-mice. Results clearly showed that sciatic nerve ligation
induced an increase of iNOS (A), COX-2 (B) and NFjB-p65 (C)
expression in the spinal cord. Acute Flu-AM4 treatment signifi-
cantly reduced this expression (Figure 8).
Conclusion
A growing body of evidence suggesting that dual inhibition of
COX and FAAH enzymes offers a potential therapeutic strategy to
attenuate inflammatory and neuropathic pain states24,31,36. The
development of dual FAAH-COX inhibitors would be of great
potential value as a therapeutic strategy to treat different types of
pain. Indeed, efforts are underway to synthesise such com-




















































Figure 6. Effect of vehicle and Flu-AM4 upon carrageenan-induced paw oedema
(A) and paw hyperalgesia (B). Five min after carrageenan injection, mice were
treated with vehicle (white circle) or Flu-AM4 (10mg/kg ip; black square). Data
are shown as mean±SEM of 6 animals per group.  p< 0.05,  p< 0.001 vs.
vehicle, unpaired t-test.
CCI-von-Frey Test


















































Figure 7. Effect of vehicle and Flu-AM4 in CCI-induced mechanical (A) and hyperalgesia (B) allodynia on day 7 and 14. Mice 1 h before test were treated with vehicle
(grey bars) and Flu-AM4 (1, 3 or 10mg/kg ip). Data are shown as mean± SEM of 6 animals per group. p< 0.05 and p< 0.01 vs. vehicle, 2-way repeated-measures
ANOVA with post-hoc Bonferroni tests.
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synthesis, the molecular mechanism of action and the pharmaco-
logical characterisation of a series of pyridine amide derivatives of
flurbiprofen. In particular, enzymatic assays identified Flu-AM4 the
most promising compound within the series, docking and molecu-
lar dynamics studies suggested the molecular basis of dual action
of pyridine-amide flurbiprofen derivatives. Moreover, our in vivo
studies clearly indicated that the administration of a dual com-
pound reduced inflammation and pain. Flu-AM4, indeed, was
able to modulate the inflammatory process developed by carra-
geenan and formalin injection restoring the expression of import-
ant enzymes such as COX-2 and iNOS in the spinal cord of
inflamed-mice. Moreover, Flu-AM4 reduced also neuropathic pain
by sciatic nerve ligation suggesting that its activity can influence
much more elaborate and chronic pathways. Our results are in
agreement with other studies where co-administration of the
FAAH inhibitor URB597 and COX-1/2 inhibitor diclofenac produced
synergistic antinociceptive effects in the acetic acid abdominal
stretching assay31. Likewise, combination of the peripherally
restricted FAAH inhibitor URB937 and the COX-1/2 inhibitor indo-
methacin significantly reduced nociceptive behaviour in the carra-
geenan and CCI models in a synergistic fashion64.
In conclusion, we have identified Flu-AM4 as a dual-action
reversible FAAH/substrate-selective COX inhibitor anti-inflamma-
tory and analgesic activity in several animal pain models. These
Figure 8. iNOS (A), COX-2 (B) and NF-jB-p65 (C) expression in the spinal cord of CCI-mice. Mice were treated 1 h before with vehicle (black bars) and Flu-AM4
(10mg/kg ip, grey bars). Sham mice represent animal without sciatic nerve ligation. Data are shown as mean± SEM of 6 animals per group; representative blot are
shown. p< 0.05 vs. sham; #p< 0.05 and ##p< 0.01 vs. vehicle, one-way repeated-measures ANOVA with post-hoc Bonferroni tests.
950 A. DEPLANO ET AL.
findings underscore the potential usefulness of such dual-action
compounds and suggest that Flu-AM4 is an ideal molecule with
which to explore further this exciting possibility.
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